Regulatory Priorities, Real-World Evidence, and the Safety and Effectiveness of COVID-19 Vaccines

Share on: 

The ways COVID-19 vaccines are being administered have changed substantially in the last few months. Issues such as mixing and matching vaccines, boosters, and vaccine use in children are fundamentally changing that landscape. These shifts make it critically important that research methods are solid; the Sentinel Initiative plays a key role in ensuring that in the US. 

The Sentinel Initiative, launched in 2007 by the US Food and Drug Administration (FDA), is a national electronic data system created to help monitor the safety of FDA-regulated products, including drugs, vaccines, biologics, and medical devices. Having a collective network of data providers and scientific collaborators enables regulators to evaluate potential safety issues rapidly.

The Sentinel system provides extensive health-data resources for safety surveillance, support for developing and applying new methods, and support for performing studies. The Biologics Effectiveness and Safety (BEST) System supports the Sentinel Initiative in monitoring the safety and effectiveness of biologic products. RTI-HS is in the trenches with CBER and other partners in the BEST System to address FDA regulatory priorities around new COVID-19 vaccines. 

RTI-HS is collaborating with the FDA to ensure that rigorous, valid methods are used to evaluate COVID-19 vaccine effectiveness in the real world. Bradley Layton, PhD, Senior Research Epidemiologist with RTI-HS, shares, “We are honored to be working with the FDA and their network of research collaborators committed to ensuring rigorous, valid research in service of public health and safety.”

Staff Members